AQUESTIVE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.07 USD | +3.56% |
|
-0.85% | +101.49% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 186.5 | 179.9 | 156.2 | 48.85 | 134.9 | 368.4 | - | - |
| Enterprise Value (EV) 1 | 197.5 | 185 | 179.8 | 73.73 | 138.5 | 348.2 | 383.9 | 377.4 |
| P/E ratio | -2.23 x | -3.22 x | -2.1 x | -0.81 x | -15.5 x | -11.4 x | -13.8 x | -74 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 3.54 x | 3.92 x | 3.07 x | 1.02 x | 2.67 x | 7.34 x | 6.35 x | 4.37 x |
| EV / Revenue | 3.75 x | 4.03 x | 3.54 x | 1.55 x | 2.74 x | 6.93 x | 6.62 x | 4.48 x |
| EV / EBITDA | -3.97 x | -4.69 x | -5.67 x | -2.09 x | -12 x | -15.1 x | -15.6 x | -24.4 x |
| EV / FCF | -3.21 x | -4.02 x | -5.3 x | -6.82 x | - | -14 x | -13 x | -18.8 x |
| FCF Yield | -31.2% | -24.9% | -18.9% | -14.7% | - | -7.15% | -7.7% | -5.33% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 32,043 | 33,620 | 40,164 | 54,156 | 66,767 | 90,528 | - | - |
| Reference price 2 | 5.820 | 5.350 | 3.890 | 0.9021 | 2.020 | 4.070 | 4.070 | 4.070 |
| Announcement Date | 3/11/20 | 3/9/21 | 3/8/22 | 3/7/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 52.61 | 45.85 | 50.83 | 47.68 | 50.58 | 50.21 | 57.98 | 84.28 |
| EBITDA 1 | -49.76 | -39.45 | -31.72 | -35.3 | -11.56 | -23.11 | -24.6 | -15.5 |
| EBIT 1 | -52.67 | -42.89 | -34.68 | -42.07 | -15.1 | -23.29 | -23.58 | -6.884 |
| Operating Margin | -100.11% | -93.55% | -68.22% | -88.23% | -29.86% | -46.38% | -40.67% | -8.17% |
| Earnings before Tax (EBT) 1 | -66.25 | -55.78 | -70.54 | -54.41 | -7.625 | -28.33 | -27.75 | -5.259 |
| Net income 1 | -66.25 | -55.78 | -70.54 | -54.41 | -7.87 | -27.72 | -27.6 | -5.259 |
| Net margin | -125.92% | -121.67% | -138.77% | -114.11% | -15.56% | -55.21% | -47.6% | -6.24% |
| EPS 2 | -2.610 | -1.660 | -1.850 | -1.120 | -0.1300 | -0.3580 | -0.2940 | -0.0550 |
| Free Cash Flow 1 | -61.55 | -45.98 | -33.89 | -10.81 | - | -24.9 | -29.55 | -20.1 |
| FCF margin | -117% | -100.28% | -66.67% | -22.68% | - | -49.59% | -50.97% | -23.85% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/11/20 | 3/9/21 | 3/8/22 | 3/7/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 13.29 | 11.08 | 12.27 | 13.26 | 11.46 | 10.68 | 11.13 | 13.24 | 13 | 13.21 | 12.26 | 12.6 | 12.59 | 12.62 | 12.75 |
| EBITDA 1 | -5.332 | -10.94 | -9.011 | -9.874 | -7.722 | -9.604 | -3.936 | -3.272 | -1.339 | -2.757 | -4.433 | -5.333 | -5.458 | -7.458 | - |
| EBIT 1 | -7.968 | -11.67 | -9.738 | -12.76 | -8.853 | -10.71 | -11.13 | -4.209 | -2.377 | -3.911 | -5.646 | -6.069 | -5.82 | -6.594 | -6.7 |
| Operating Margin | -59.97% | -105.33% | -79.36% | -96.21% | -77.23% | -100.29% | -100% | -31.79% | -18.28% | -29.62% | -46.04% | -48.15% | -46.24% | -52.23% | -52.55% |
| Earnings before Tax (EBT) 1 | -14.56 | -28.94 | -13.22 | -16.3 | -12.54 | -12.35 | 8.068 | -5.508 | -2.175 | -8.01 | -6.293 | -7.105 | -7.031 | -7.949 | - |
| Net income 1 | -14.56 | -28.94 | -13.22 | -16.3 | -12.54 | -12.35 | 8.068 | -5.792 | -2.035 | -8.111 | -6.243 | -7.055 | -6.981 | -7.899 | - |
| Net margin | -109.54% | -261.28% | -107.74% | -122.89% | -109.36% | -115.63% | 72.46% | -43.74% | -15.65% | -61.42% | -50.91% | -55.97% | -55.46% | -62.57% | - |
| EPS 2 | -0.3700 | -0.7300 | -0.3200 | -0.3600 | -0.2300 | -0.2300 | 0.1100 | -0.1000 | -0.0300 | -0.1200 | -0.0800 | -0.0880 | -0.0900 | -0.1020 | -0.0700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/2/21 | 3/8/22 | 5/4/22 | 8/2/22 | 11/1/22 | 3/7/23 | 5/2/23 | 8/7/23 | 11/6/23 | 3/5/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 11 | 5.1 | 23.5 | 24.9 | 3.66 | - | 15.5 | 8.99 |
| Net Cash position 1 | - | - | - | - | - | 20.2 | - | - |
| Leverage (Debt/EBITDA) | -0.2213 x | -0.1292 x | -0.7418 x | -0.7047 x | -0.3165 x | - | -0.6287 x | -0.5799 x |
| Free Cash Flow 1 | -61.6 | -46 | -33.9 | -10.8 | - | -24.9 | -29.6 | -20.1 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.66 | 0.52 | 0.91 | 1.02 | - | 1.5 | 1.75 | 1.75 |
| Capex / Sales | 1.26% | 1.13% | 1.8% | 2.15% | - | 2.99% | 3.02% | 2.08% |
| Announcement Date | 3/11/20 | 3/9/21 | 3/8/22 | 3/7/23 | 3/5/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.07
USD
Average target price
9
USD
Spread / Average Target
+121.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +101.49% | 368M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- AQST Stock
- Financials Aquestive Therapeutics, Inc.
